微门户首页  新闻  讨论区  活动  博客  求职招聘  行业报告  圈内成员  供应   
已读[52] 发布: 2014/05/09 05:50:10
Business Wire (press release) The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be ... and more »
已读[45] 发布: 2014/05/09 05:50:05
DigitalJournal.com Research and Development Forecast of China Heparin Industry to 2017 mainly analyzes the global and domestic market status quo of heparin industry, development conditions of heparin upstream and downstream industry, the supply and demand of major ... and more »
已读[51] 发布: 2014/05/09 05:49:50
Pharmacy Times Heparin -induced thrombocytopenia (HIT) is a well-described adverse drug reaction that can occur with heparin administration and lead to devastating thromboembolic complications.1 HIT is the most frequent drug-induced type of thrombocytopenia and is ...
已读[44] 发布: 2014/05/09 05:49:42
TCTMD In patients undergoing percutaneous coronary intervention (PCI) for either non-ST-segment elevation acute coronary syndromes (NSTE-ACS) or stable ischemic heart disease, bivalirudin is associated with less bleeding compared with unfractionated heparin  ...
已读[140] 发布: 2014/05/09 05:11:05
公司生产阿维菌素及伊维菌素原料药产量为亚洲最大,分别占中国与世界总产量30%和25%以上;甲胺基阿维菌素、苯甲酸盐和乙酰基阿维菌素产量为中国之首,占国内总产量60...
已读[66] 发布: 2014/05/07 03:53:19
“肝素系列产品产业化项目”之子项目“精制肝素原料药产能扩大项目”与“低分子量肝素原料药研发和产业化项目”为公司优势产品肝素钠原料药和低分子肝素钙原料药的...
已读[306] 发布: 2014/05/07 03:52:43
因此需考虑应用低分子肝素进行抗凝治疗的过渡或桥接。但低分子肝素治疗同样可增加围术期出血风险,因此确定是否进行抗凝桥接治疗前应审慎评估患者的获益风险比,只有在...
已读[63] 发布: 2014/05/07 03:52:38
并且,随着低分子肝素仿制药陆续上市,制剂价格将进一步降低,下游制剂企业对肝素原料药降价的需求凸显。受此影响,预计未来肝素原料药价格仍有下降的可能。 随着医药行业...
已读[55] 发布: 2014/05/07 03:52:33
低分子肝素钙持续高增长:公司一季度水针制剂实现销售9939 万元,同比增长33%,实现销量300 万支,较上年同期增长25.6%,其中核心产品低分子肝素钙增长28%,在淡季...
已读[56] 发布: 2014/05/07 03:52:26
“肝素系列产品产业化项目”之子项目“精制肝素原料药产能扩大项目”与“低分子量肝素原料药研发和产业化项目”为公司优势产品肝素钠原料药和低分子肝素钙原料药的...
« 上一页  |   查看结果1631-1640共2625   |  下一页 »



最新报告


求职招聘